Bioanalytical Support of Biosimilars:
Expect the Unexpected
About this webinar
The success of early clinical studies comparing a biosimilar drug candidate with the innovator compound is not only dependent on the similarity of the products themselves but also on the quality of the bioanalytical assay methods and the design and conduct of early PK/PD studies. Based on experiences gained from support of the first wave of biosimilar products to gain approval in the US and EU, Celerion will share key learnings gained from engagement with several biosimilar programs. This includes the rationale for the one assay approach and how the two-step approach can help set up such an assay.
Establishing a robust validation of a single assay with both the innovator and biosimilar compound aims to show analytical similarity and confirmation of comparable reactivity. This includes challenges in pushing the limit of precision of ligand binding assays, which is essential when processing samples from biosimilar studies, and how adapted routine analysis best practices can overcome those challenges.
In this webinar, the speakers will:
- Discuss the direct impact of the bioanalytical assay set-up on the statistical endpoint and, therefore, on the success of early clinical studies comparing a biosimilar drug candidate with the innovator compound
- Share key learnings gained from several biosimilar programs
- Learn the rationale for the one assay approach and how the two-step approach can support this assay
- Get insight into how reagents can impact the assay performance
Register for this webinar to learn about best practices for analytical assay method development for comparing a biosimilar candidate with its innovator compound.
Who should attend
- Heads of Research and Development
- Clinical Pharmacologists
- Project Managers
- Medical Directors
- Clinical Operations Directors, Managers
- Clinical Planning Directors, Managers
- Bioanalytical Scientists
What you will learn
- Discuss the direct impact of the bioanalytical assay set-up on the statistical endpoint and, therefore, on the success of early clinical studies comparing a biosimilar drug candidate with the innovator compound
- Share key learnings gained from engagement with several biosimilar programs
- Learn the rationale for the one assay approach and how the two-step approach can help set up such an assay
- Get insight into how reagents can impact the assay performance
Featured Speakers
Dr. Petra Struwe
Dr. Petra Struwe is the Executive Director of Bioanalytical Services at the Celerion facility in Switzerland, a contract research organization (CRO) supporting biopharmaceutical industry drug development. She holds a PhD in chemistry and is an experienced scientific leader with more than 20 years working in the Bioanalytical and Biomarker segment of the pharmaceutical industry. In her current role she is in charge of both small and large molecule method development/validation and sample processing in an extremely automated and compliant environment.
Partner for this event
Celerion
Celerion, a global leader in early clinical research services offers a unique combination of medical expertise, clinical operations experience and scientific excellence that gives our clients the confidence to make fast, accurate decisions about their drug development path. For fifty years, Celerion has leveraged the latest operational concepts and technologies to execute safety/tolerability, pharmacokinetic and pharmacodynamics studies in highly controlled clinic environments. These include first-in-human dose escalation, drug-drug interaction, cardiac safety, bioequivalence and bioavailability, metabolism and excretion studies as well as pharmacokinetic evaluations in patients with impaired renal or hepatic function. Celerion offers feasibility, data management, biostatistics, clinical monitoring, and bioanalytical services. Our founding mission is to help our clients get their drugs to market quickly, so that they touch the lives of our family, friends and people in need around the world. For more information, please visit www.celerion.com.
Related webinars
More from Celerion.
Drug Labeling Studies in Clinical Pharmacology: Recent FDA/EMA Updates
AAV Vector Shedding Assay— Best Practices in Clinical Gene Therapy Method Development
Nitrosamine Impurities in Rifampin – What Does it Mean for Your Drug-Drug Interaction (DDI) Study?
Onsite Pharmacy Compounding for Your Phase 1 Clinical Study
Clinical and Bioanalytical Aspects of Immune Monitoring via ELISpot
Introducing Laboratory Automation into a Regulated Environment: From Proof-Of-Principle to High-End Solutions
ADME 101: Lessons on Running a Successful Clinical Mass Balance Trial
Biosimilar Development: Lessons Learned from Early Clinical Studies
NAFLD/NASH – Race to the Market: Strategies and Tactics to Address Unmet Needs